Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2009 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (179)	2/11/2009 5:42:26 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 418

Rick, Thanks for the feed back! I did pick up a small position late Friday.....very small! I do have some reservation about their latest PIPE deal, but guess in this market environment they had no other option. Also, I would have preferred that Bayer had taken more than just an option on a drug candidate. Did you by chance look at their slide presentation at BIO yesterday? If not, it's available on their website. The reason I ask is that on the final slide it names the management team and the CEO has Stanford University down. By taking a tetanus shot, I visited the Yahoo board where a poster indicates that the CEO doesn't have a degree from Stanford. For several of the team on this slide they just indicate places they had worked, so could it be that Ilin maybe worked at Stanford at one point. If these guys are fudging their resumes......that is a big red flag for me! Thanks again for the input! Cary

To: scaram(o)uche who wrote (179)	2/12/2009 11:10:24 AM
From: Biomaven	Read Replies (2) \| Respond to of 418

One issue with Micromet that they play down a lot (e.g., by not mentioning it in presentations at all) is the very short half-life of their drug. That means it's delivered right now via a continuous infusion pump over something like a month. Eventually they could move to a subcutaneous pump. If the results continue to be dramatic this may not matter that much, but it certainly does raise the bar as to what constitutes efficacy for them. Peter